Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
- PMID: 31378236
- DOI: 10.1016/j.mayocp.2019.01.013
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Abstract
Lung cancer remains the leading cause of cancer deaths in the United States. In the past decade, significant advances have been made in the science of non-small cell lung cancer (NSCLC). Screening has been introduced with the goal of early detection. The National Lung Screening Trial found a lung cancer mortality benefit of 20% and a 6.7% decrease in all-cause mortality with the use of low-dose chest computed tomography in high-risk individuals. The treatment of lung cancer has also evolved with the introduction of several lines of tyrosine kinase inhibitors in patients with EGFR, ALK, ROS1, and NTRK mutations. Similarly, immune checkpoint inhibitors (ICIs) have dramatically changed the landscape of NSCLC treatment. Furthermore, the results of new trials continue to help us understand the role of these novel agents and which patients are more likely to benefit; ICIs are now part of the first-line NSCLC treatment armamentarium as monotherapy, combined with chemotherapy, or after definite chemoradiotherapy in patients with stage III unresectable NSCLC. Expression of programmed cell death protein-ligand 1 in malignant cells has been studied as a potential biomarker for response to ICIs. However, important drawbacks exist that limit its discriminatory potential. Identification of accurate predictive biomarkers beyond programmed cell death protein-ligand 1 expression remains essential to select the most appropriate candidates for ICI therapy. Many questions remain unanswered regarding the proper sequence and combinations of these new agents; however, the field is moving rapidly, and the overall direction is optimistic.
Copyright © 2019 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Update 2020: Management of Non-Small Cell Lung Cancer.Lung. 2020 Dec;198(6):897-907. doi: 10.1007/s00408-020-00407-5. Epub 2020 Nov 11. Lung. 2020. PMID: 33175991 Free PMC article. Review.
-
Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.Expert Opin Biol Ther. 2016 Oct;16(10):1209-23. doi: 10.1080/14712598.2016.1214265. Epub 2016 Aug 5. Expert Opin Biol Ther. 2016. PMID: 27426430 Review.
-
Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).J UOEH. 2018;40(2):173-189. doi: 10.7888/juoeh.40.173. J UOEH. 2018. PMID: 29925736 Review.
-
The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.Clin Lung Cancer. 2018 Mar;19(2):120-129. doi: 10.1016/j.cllc.2017.10.014. Epub 2017 Oct 28. Clin Lung Cancer. 2018. PMID: 29153898 Review.
-
Updates in non-small cell lung cancer.Clin J Oncol Nurs. 2008 Aug;12(4):587-96. doi: 10.1188/08.CJON.587-596. Clin J Oncol Nurs. 2008. PMID: 18676326 Review.
Cited by
-
Mining and evaluation of adverse event signals for capmatinib based on the FAERS database.Front Pharmacol. 2024 Sep 24;15:1417661. doi: 10.3389/fphar.2024.1417661. eCollection 2024. Front Pharmacol. 2024. PMID: 39380910 Free PMC article.
-
Efficacy and safety of camrelizumab-based comprehensive treatment for non-small cell lung cancer: a systematic review and meta-analysis.Ther Adv Med Oncol. 2024 Oct 4;16:17588359241284904. doi: 10.1177/17588359241284904. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39376584 Free PMC article.
-
CHAC1 blockade suppresses progression of lung adenocarcinoma by interfering with glucose metabolism via hijacking PKM2 nuclear translocation.Cell Death Dis. 2024 Oct 5;15(10):728. doi: 10.1038/s41419-024-07114-6. Cell Death Dis. 2024. PMID: 39368995 Free PMC article.
-
Weight loss as a predictor of reduced survival in patients with lung cancer: a systematic review with meta-analysis.Int J Obes (Lond). 2024 Oct 3. doi: 10.1038/s41366-024-01642-z. Online ahead of print. Int J Obes (Lond). 2024. PMID: 39363034
-
The value of non-enhanced CT 3D visualization in differentiating stage Ⅰ invasive lung adenocarcinoma between LPA and non-LPA.Eur J Radiol Open. 2024 Sep 21;13:100600. doi: 10.1016/j.ejro.2024.100600. eCollection 2024 Dec. Eur J Radiol Open. 2024. PMID: 39351522 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous